MedTrace Logo

Atacicept in Subjects With IgA Nephropathy

NCT04716231 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 376

Last updated 2025-09-30

No results posted yet for this study

Summary

A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)

Conditions

Interventions

BIOLOGICAL

Atacicept

Once weekly subcutaneous (SC) injections by prefilled syringe

OTHER

Placebo to match Atacicept

Once weekly subcutaneous (SC) injections by prefilled syringe

Sponsors & Collaborators

  • Vera Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Zeeshan Khawaja · Vice President, Clinical Development

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-29
Primary Completion
2025-05-15
Completion
2028-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04716231 on ClinicalTrials.gov